XML 27 R17.htm IDEA: XBRL DOCUMENT v3.25.3
Goodwill and Intangible Assets, Net
 9 Months Ended
Sep. 28, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net
The Company tests goodwill at least annually for possible impairment. The Company completes the annual testing of impairment for goodwill on the later of November 1 or the first day of its eleventh fiscal month of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill.
The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. The Company performed its annual impairment testing for its reporting units for fiscal year 2024 as of November 1, 2024. There were no impairments measured in the periods presented. While the Company believes that its estimates of current value are reasonable, if actual results differ from the estimates and judgments used, including such items as future cash flows and the volatility inherent in markets which the Company serves, impairment charges against the carrying value of those assets could be required in the future.
The changes in the carrying amount of goodwill for the nine months ended September 28, 2025 were as follows:
Life SciencesDiagnosticsConsolidated
 (In thousands)
Balance at December 29, 2024$4,541,467 $1,922,152 $6,463,619 
Foreign currency translation96,267 40,745 137,012 
Acquisitions, earn-outs and other98 (98)— 
Balance at September 28, 2025$4,637,832 $1,962,799 $6,600,631 
Identifiable intangible asset balances by category were as follows:
September 28,
2025		December 29,
2024
 (In thousands)
Patents$27,805 $27,808 
Less: Accumulated amortization(26,467)(26,293)
Net patents1,338 1,515 
Trade names and trademarks149,468 142,588 
Less: Accumulated amortization(99,392)(87,824)
Net trade names and trademarks50,076 54,764 
Licenses27,487 27,164 
Less: Accumulated amortization(19,395)(17,855)
Net licenses8,092 9,309 
Core technology1,618,415 1,561,831 
Less: Accumulated amortization(881,299)(735,532)
Net core technology737,116 826,299 
Customer relationships2,859,641 2,807,909 
Less: Accumulated amortization(1,230,337)(1,058,875)
Net customer relationships1,629,304 1,749,034 
Total$2,425,926 $2,640,921 
Total amortization expense related to amortizable intangible assets was $84.1 million and $252.1 million for the three and nine months ended September 28, 2025, respectively, and $89.6 million and $271.5 million for the three and nine months ended September 29, 2024, respectively. Estimated amortization expense related to amortizable intangible assets is $84.6 million for the remainder of fiscal year 2025, $332.1 million for fiscal year 2026, $304.6 million for fiscal year 2027, $278.6 million for fiscal year 2028, and $249.2 million for fiscal year 2029